Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an announcement.
RemeGen Co., Ltd. announced the resignation of Dr. He Ruyi from his roles as an executive director, member of the strategy committee, chief strategic officer, and core technical personnel. His resignation, effective February 6, 2025, is due to personal career development and will not impact the company’s operations or board activities. The company has expressed gratitude for Dr. He’s contributions and plans to conduct a by-election for his replacement.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company based in China, focusing on innovative drug discovery and development. The company is listed on the Stock Exchange of Hong Kong and engages in the development of therapeutics for various medical conditions.
YTD Price Performance: -9.17%
Average Trading Volume: 1,556,837
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$13.01B
For an in-depth examination of 9995 stock, go to TipRanks’ Stock Analysis page.